| UltraShape Appoints Mike Berman as Chairman |
| 06 December 2005 |
|
Tel-Aviv, Israel- December 6, 2005- UltraShape Ltd., a leader in non-invasive aesthetic medicine, today announced that Mr. Mike Berman, former president of Boston Scientific’s Cardiovascular business, has been appointed Chairman of the Board of Directors. “We are delighted to have someone of Mr. Berman’s talent join our distinguished board of directors. His extensive background in the medical device field, combined with his proven record of successfully building and growing companies, promises to enhance the company’s leadership” said Yoram Eshel, PhD, UltraShape’s Chief Executive Officer. “I am excited about joining the UltraShape team. The aesthetics market is large, growing, and has tremendous potential. I am confident that UltraShape’s non-invasive products will have a large impact on the field”, said Mike Berman. Mr. Berman is a medical device entrepreneur working with a select group of high potential development and early commercial stage companies. From 1995 to 2000, Mr. Berman was President of Boston Scientific Cardiology. Under his leadership, Boston Scientific Cardiology increased worldwide sales from $400 million to $1.4 billion. About UltraShape:UltraShape is redefining aesthetic medicine by developing, manufacturing and marketing innovative non-invasive devices for body contouring. The Company is dedicated to providing healthcare professionals with leading edge solutions that enhance the lives of patients worldwide. The UltraShape proprietary technology is based on focused ultrasound waves that selectively disrupt adipose (fat) cells without affecting surrounding tissues. The safety and effectiveness of the UltraShape surgery-free solution has been clinically proven in hundreds of patients. The Company’s products are marketed in over 20 countries. UltraShape Ltd. is a privately held company founded in 2000. For more information visit www.ultrashape.com. |